

CancerCare Manitoba Small Group Sessions

Hepatobiliary Cancers

June 14 - 15, 2024



Program

Holiday Inn Winnipeg Airport West
2520 Portage Avenue, Winnipeg, MB

This Group Learning activity has been certified by the College of Family Physicians of Canada and the Manitoba Chapter for up to 7.25 Mainpro+ Certified credits

Hepatobiliary Educational Program

Small Group Sessions | June 14-15, 2024

Holiday Inn Winnipeg Airport West | 2520 Portage Ave, Winnipeg, MB



Schedule at a Glance

Friday - Evening (Dauphin/Brandon Room)

| | |
|--------------------|---|
| 18:00-18:15 | Registration |
| 18:15-19:15 | Welcome and Dinner |
| 19:15-20:15 | How are You Challenged Managing Patients with Liver Lesions? Dr. Marie Noel |

Saturday - All Day (Dauphin/Brandon Room)

| | |
|--------------------|---|
| 07:00-08:00 | Breakfast (Thompson Room) |
| 08:00-08:30 | Hepatocellular Carcinoma Screening, Diagnosis and Staging Dr. David Peretz |
| 08:30-08:40 | <i>Questions and Discussion</i> |
| 08:40-09:10 | Viral Hepatitis in Your Practice Dr. Kelly Kaita |
| 09:10-09:20 | <i>Questions and Discussion</i> |
| 09:20-09:40 | Role of Surgery in the Multidisciplinary Management of Primary and Secondary Liver Cancer Dr. Lev Bubis |
| 09:40-09:50 | <i>Questions and Discussion</i> |
| 09:50-10:10 | Nutrition Break - 20 minutes (Thompson Room) |
| 10:10-10:30 | We DeLiver Mayah Duque |
| 10:30-10:40 | <i>Questions and Discussion</i> |
| 10:40-11:10 | Interventional Procedures for the Management of Liver Cancers Dr. Alessandra Cassano-Bailey |
| 11:10-11:20 | <i>Questions and Discussion</i> |
| 11:20-11:50 | Role of Stereotactic Body Radiation Therapy in the Management of Primary and Secondary Liver Cancers Dr. Maged Nashed |
| 11:50-12:00 | <i>Questions and Discussion</i> |
| 12:00-13:00 | Lunch - 60 minutes (Thompson Room) |
| 13:00-13:20 | Introduction to the New Hepatocellular Carcinoma Management Document Dr. Maged Nashed |



| | |
|--------------------|---|
| 13:20-13:40 | Systemic Therapy for Hepatocellular Carcinoma Dr. Paul Daeninck |
| 13:40-14:00 | Management of Systemic Therapy Side Effects Dr. Vallerie Gordon |
| 14:00-14:20 | <i>Questions and Discussion</i> |
| 14:20-14:40 | Nutrition Break - 20 minutes (Thompson Room) |
| 14:40-15:00 | Palliative Care in Hepatobiliary Cancers Stephanie Lelond |
| 15:00-15:10 | <i>Questions and Discussion</i> |
| 15:10-15:50 | Case Discussion and Reflection on Learning and Liver Community of Practice Dr. Tunji Fatoye |
| 15:50-16:00 | Concluding Remarks and Evaluations Dr. Tunji Fatoye |

Agenda subject to change.



Friday, May 10, 2024

How are You Challenged Managing Patients with Liver Lesions?



Speaker

Marie Noel, MD, FPO with the Northern Regional Health Authority

Learning Objectives

During this session, participants will:

1. Explore the challenges faced by healthcare providers in diagnosing and treating patients with hepatobiliary cancers
2. Share personal experiences in caring for patients with hepatobiliary cancers
3. Formulate personal learning objectives for the following educational day

Biographical Sketch

I am a family physician who lives in the Pas and works in the Northern Health Region primarily as a family physician for almost 20 years. I have been a part of CCMB as a Family Physician in Oncology since 2015. Other clinical roles include episodic care in the personal care home, The Pas Correctional Centre and the hemodialysis unit.

On a personal note, I have a partner who excels in IT and graciously assists my use of computers and smartphones, and we share two dogs and a cat. My new hobby outside of work is learning to play the piano.



Saturday, May 11, 2024

Hepatocellular Carcinoma Screening, Diagnosis and Staging



Speaker

Dr. David Peretz, MS, MD, FRCPC, Director Manitoba Liver Transplant Program,
Director, Manitoba Liver Transplant Program

Learning Objectives

At the end of the session, participants will be able to:

1. Identify who should be screened for hepatocellular carcinoma
2. Describe the screening process
3. Explain how to stage hepatocellular carcinoma

Biographical Sketch

David Peretz, MD, MSc, FRCPC, specializes in Gastroenterology and Hepatology at the University of Manitoba and is currently serving as assistant professor and director of the liver transplant program. He is the AFC hepatology program director for postgraduate trainees interested in furthering their education in hepatology. Dr. Peretz is a member of the American Association for the Study of Liver Disease (AASLD), the Canadian Association for the Study of Liver Disease (CASL), and the Canadian Association of Gastroenterology (CAG). He is certified by the American Board of Internal Medicine (ABIM) and the Royal College of Physicians (FRCP) in Internal Medicine and Gastroenterology. He received his subspecialty training in gastroenterology and hepatology at the University of Manitoba and transplant hepatology at Ochsner in New Orleans.



Viral Hepatitis in Your Practice



Speaker

Dr. Kelly Kaita, MD, FRCP(C), FASSLD, Director, VHIU, University of Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. Discuss the basic virology and epidemiology of HBV
2. Expand and illustrate knowledge of HBV diagnostics
3. Review the natural history of HBV
4. Explain what “resolved HBV infection” is and concerns for the patient while using immunosuppressive therapy.
5. Determine when antiviral therapy is indicated vs a “wait and watch” approach

Biographical Sketch

Dr. Kaita is currently the director of the Viral Hepatitis Investigative Unit (VHIU) at the Health Sciences Centre, University of Manitoba. The VHIU started in 1997 and continues to grow and provides the most up-to-date and experimental therapies for patients affected by viral hepatitis. This unit has proven to be a National Center of Excellence and is used as a framework for other units across the country and the United States.

Dr. Kaita graduated from Internal medicine at the University of Manitoba and then completed his liver training at the University of Manitoba and Western Ontario. The Viral Hepatitis Investigative Unit has been involved in the development of all the current therapies for viral hepatitis.



Role of Surgery in the Multidisciplinary Management of Primary and Secondary Liver Cancers



Speaker

Dr. Lev Bubis, MD, FRCSC, Assistant Professor, University of Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. Explain the role of surgery in the treatment of liver cancers
2. Discuss the importance of early hepatobiliary surgery assessment in newly diagnosed patients
3. Describe how surgery fits into a multidisciplinary framework of liver cancer care

Biographical Sketch

Dr. Bubis is a hepatobiliary and pancreatic surgeon at the Winnipeg Health Sciences Centre and an assistant professor of surgery at the University of Manitoba. His practice focuses on HPB and complex upper GI surgical oncology. He did his residency training at the University of Toronto, followed by a combined fellowship in HPB surgery and complex general surgical oncology at the same institution.



We DeLiver

Speaker

Mayah Duque, RN, BN, Nurse Navigator/Liver Navigation Lead

Learning Objectives

At the end of the session, participants will be able to:

1. Explain the role of the Navigation Liver Lead in patients with high suspicion of a Liver Malignancy
2. Identify When and How to Connect with the Navigation Services.
3. Summarize the minimum required investigations for patients with suspected Liver Malignancy.

Biographical Sketch

Mayah graduated in 1993 in the Philippines and started her nursing career in Detroit, Michigan, in 1995. She worked in various oncology wards at Detroit Sinai Hospital until 2002. Mayah became a Travelling Nurse in 2003 and worked at Harborview Hospital in Seattle, Washington. She moved to Vancouver in 2004 and worked in the Treatment Room at the Royal Columbian Hospital. She moved to Winnipeg for love and started working at CancerCare Manitoba in 2008 in the Surgical Oncology Clinic. She worked in the Breast Clinic with Dr. L. Brandes in 2008 and is one of the Pioneer Nurses of the Urgent Cancer Care Clinic. She is also one of the nurses who started the Winnipeg Navigation Services in November 2014.



Interventional Procedures for the Management of Liver Cancers



Speaker

Dr. Alessandra Cassano-Bailey, MD, FRCPC, Interventional Radiologist

Learning Objectives

At the end of the session, participants will be able to:

1. Describe the common diagnostic and therapeutic procedures commonly performed by Interventional Radiology for the treatment and diagnosis of primary and metastatic liver cancers.
2. Identify the difference between Radiofrequency vs Microwave Ablation and describe at least two advantages of the latter.
3. Describe how to identify correct position of internal/external biliary drains and identify two common causes of bile leakage around drain exit sites.
4. Describe the role of bland embolization in the setting of bleeding metastases.

Biographical Sketch

Dr Cassano-Bailey is an Assistant Professor of Radiology at the University of Manitoba. She has been practicing at the Health Sciences Center since 2012, specializing in locoregional Cancer treatments. She is the current president of the Canadian Association of Interventional Radiology.



Role of Stereotactic Body Radiation Therapy in the Management of Primary and Secondary Liver Cancers



Speaker

Dr. Maged Nashed, FRCPC, PhD

Learning Objectives

At the end of the session, participants will be able to:

1. List the three main differences between the standard fractionated external beam radiation and stereotactic body radiation therapy (SBRT).
2. Describe the indications of SBRT in the management of primary and secondary liver malignancies.
3. Diagnose and manage radiation-induced liver disease.

Biographical Sketch

Dr. Nashed graduated from Medical School at Cairo University, Egypt and received training in clinical oncology in the UK. Dr. Nashed obtained FRCPC and has worked as a Radiation Oncologist at CancerCare Manitoba (CCMB) since 2009.



Introduction to the New Hepatocellular Carcinoma Management Document



Speaker

Dr. Maged Nashed, FRCPC, PhD

Learning Objectives

At the end of the session, participants will be able to:

1. Identify the three main factors that influence management decisions of hepatocellular carcinoma (HCC).
2. Describe the basics of how to select the treatment modality in patients with inoperable HCC.
3. List the main requirements when referring a patient to CancerCare Manitoba.

Biographical Sketch

Dr. Nashed graduated from Medical School at Cairo University, Egypt and received training in clinical oncology in the UK. Dr. Nashed obtained FRCPC and has worked as a Radiation Oncologist at CancerCare Manitoba (CCMB) since 2009.



Systemic Therapy for Hepatocellular Carcinoma

Speaker

Dr. Paul Daeninck, MD, MSc, FRCPC, Medical Oncologist/Palliative Medicine Consultant, CancerCare Manitoba, University of Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. List the therapeutic options for treatment of Hepatocellular Carcinoma (HCC)
2. Review the suitability of patients with HCC for systemic treatment
3. Share and compare CCMB formulary to the recently published ASCO guidelines for systemic therapy of HCC

Biographical Sketch

Dr. Paul Daeninck is a palliative medicine consultant and medical oncologist with CancerCare Manitoba and the Winnipeg Regional Palliative Care Program. He is the Chair of the Symptom Management and Palliative Care Disease Site at CancerCare Manitoba and is an Assistant Professor in the Max Rady College of Medicine, University of Manitoba. He is the attending physician for Jocelyn House Hospice.

Dr. Daeninck has served with several national organizations, including the Canadian Society of Palliative Care Physicians, Canadian Partnership Against Cancer, Canadian Consortium for the Investigation of Cannabinoids, and is currently the Co-Chair of the Royal College Palliative Medicine Sub-specialty Exam Committee.

Dr. Daeninck is the author of several research papers as well as textbook chapters. He serves as a reviewer for several medical journals. He has been active in the education of medical professionals and has ongoing research interests in palliative medicine, including cannabinoid use and psychedelic-assisted therapy in people who have cancer.



Management of Systemic Therapy Side Effects



Speaker

Dr. Vallerie Gordon, MD, FRCPC, Associate Professor, Medical Oncologist, CancerCare Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. To illustrate the general principles of management of immune related adverse events (irAEs)
2. To describe the more common irAEs seen in patients who are undergoing immunotherapy
3. To review the management of common irAEs
4. To discuss retreatment after the development of irA

Biographical Sketch

Dr. Gordon is a medical oncologist and Associate Professor at CancerCare Manitoba in the University of Manitoba. She completed her basic science degree at the University of Manitoba, as well as her MD degree, with a residency at the University of Manitoba in internal medicine and subspecialty training and medical oncology. She completed fellowship training to subspecialize in gastrointestinal and breast cancers at the University of Manitoba and CancerCare Manitoba, and head and neck subspecialty training at the University of Toronto, Princess Margaret Hospital.

Her clinical interests include gastrointestinal cancers, breast cancer, head and neck cancer, and thyroid cancer. She is also the medical director for the systemic therapy program and is actively involved in medical education. She was formerly the program director for medical oncology and continues to be involved in the RPC at the medical oncology program level at the University of Manitoba. She is actively involved nationally as the chair of the gastrointestinal disease site group at CancerCare Manitoba and cochair of the rectal cancer disease-oriented group through the Canadian Clinical Trials Group.



Palliative Care in Hepatobiliary Cancers



Speaker

Stephanie Lelond, RN MN CHPCN(C), Clinical Nurse Specialist, Advanced Cancers, CancerCare Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. Explain when and how to initiate a palliative approach in hepatobiliary cancers
2. Discuss the pt experience of advanced hepatobiliary cancers
3. Identify Primary Care opportunities in advanced hepatobiliary cancers

Biographical Sketch

Stephanie is a Masters prepared Registered Nurse with over 14 years of clinical practice. Currently working as an Advanced Practice Nurse- Clinical Nurse Specialist in Early Palliative Care at CancerCare Manitoba, she is dedicated to providing education and improved access to expert symptom management, patient-centred care, coping support, and goals of care discussions in advanced cancers.

Stephanie received her Nursing Baccalaureate and Master of Nursing degrees at the University of Manitoba and is a strong advocate for advanced nursing practice, palliative care, and contribution to the community. She is passionate about nurse-led research, innovative solutions, responsible financial stewardship, and sustainable data collection to demonstrate the value of nursing contribution.

As a clinician and researcher, Stephanie has focused on early palliative care, advanced pancreatic cancer, patient-centred care, and decision-making in advanced cancer. She also serves as the Director of Policy and Advocacy for the Canadian Association of Nurses in Oncology/Association Canadienne des Infirmières en Oncologie and a board member for the Association of Regulated Nurses of Manitoba.



Case Discussion and Reflection on Learning and Liver Community of Practice



Speaker

Dr. Tunji Fatoye, MBBS, FCFP, Head of the Department of Primary Care Oncology, CancerCare Manitoba

Learning Objectives

At the end of the session, participants will be able to:

1. Bring challenging cases in their practice/experience forward for discussion
2. Discuss and list various diagnostic pathways available in Manitoba
3. Clarify referral pathway questions
4. Ask/receive answers to questions they may have about their patients

Biographical Sketch

Family Physician in Oncology at CancerCare Manitoba and Academic Family Physician with the Department of Family Medicine, University of Manitoba.



Certificate of Attendance

CONTINUING PROFESSIONAL DEVELOPMENT

This is to certify that

<Name>

has completed the Continuing Professional Development program entitled

Hepatobiliary Small Group Sessions

CERT+ SESSION ID# 202236-002

on

June 14-15, 2024

Holiday Inn Winnipeg Airport West, Winnipeg, Manitoba

Credits for Family Physicians

This Group Learning activity has been certified by the College of Family Physicians of Canada and the Manitoba Chapter for 7.25 Mainpro+ Certified credits.

*This program has received an educational grant from
AstraZeneca, Bristol Myers Squibb, Dynacare, Incyte Biosciences,
Knight, Merck, Roche, Varian*

Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login Please retain proof of your participation for six (6) years in case you are selected to participate in credit validation or auditing.



This program has received support in the form of an educational grant from:

Advocate Sponsors



Supporter Sponsors

Bristol-Meyers Squibb

Dynacare

Hoffman La Roche

Incyte Biosciences Canada

Knight Therapeutics Inc.

Scan this QR code to access
the Evaluation Form

